Skip to main content
Clinical Trials/CTRI/2017/01/007626
CTRI/2017/01/007626
Not yet recruiting
未知

Comparison of conventional clinic follow up with clinician led video follow up in newly diagnosed patients with intermediate and high grade glioma undergoing adjuvant temozolomide therapy - SHADOW

Tata Memorial Hospital0 sites65 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Patients with Intermediate -high grade glioma ( WHO grade 2- 4 gliomas undergoing adjuvant temozolomide therapy
Sponsor
Tata Memorial Hospital
Enrollment
65
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Participants must be post radical chemoradiation for a histologically confirmed newly diagnosed grade II\-IV Glioma.
  • 2\.Participants must warrant adjuvant temozolomide
  • 3\.Age : Any age above 18 years. No maximum age.
  • 4\.Post first 2 cycles of adjuvant temozolomide
  • 5\.ECOG performance status \<\=2
  • 6\.Feasibility of doing video call at native place. Either internet based video call service or a smartphone based video call service. For internet based service either presence of skype or any other equivalent service for video call. For smartphone based video call presence of either a 3G or 4G service. For internet based video call presence of a webcam based camera of 480 pixels or more. For smartphone based video call presence of a front facing camera of 1\.3 megapixels or more.
  • 7\.Participants must have normal organ and marrow function as defined below:
  • a.Leukocytes\>\=2,500/mcL or ANC \>\= 1000
  • b.Platelets\>\=100,000/mcL
  • c.Total bilirubin \< 1\.5 Ã? institutional upper limit of normal

Exclusion Criteria

  • 1\.Participants who had life threatening complications either during CTRT with temozolomide or during first 2 cycles of temozolomide
  • 2\.Participants who are receiving any other investigational agents.
  • 3\.History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study.
  • 4\.Uncontrolled intercurrent illness including, but not limited to, hypertension, tuberculosis, diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, renal failure (on dialysis), active gastrointestinal bleeding, cerebrovascular accidents, inflammatory bowel disease, known hyperkalemia ( CTCAE version 4\.02 grade 3 or above which is persistent over 1 week) or psychiatric illness/social situations that would limit compliance with study requirements.
  • 5\.Pregnant women and breastfeeding women are excluded from this study because temozolomide has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants. These potential risks may also apply to other agents used in this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials